The beginning of the end: Eliquis sales forecast to plummet as EU patent expiry nears

This year, sales of Bristol Myers Squibb’s (BMS) and Pfizer’s drug Eliquis (apixaban) are projected to decline by 15.2% due to the loss of its European market exclusivity on 19 May 2026. The BMS-Pfizer alliance has dominated the anticoagulant drug market, earning approximately $82.6bn in revenue since 2011, according to GlobalData’s Sales and Forecast Database. However, with the expiry date fast approaching, the loss of Eliquis’ exclusivity will inevitably mark the beginningof a major patent cliff. Eliqu ...